Microbiology Testing Market Segmentation:
Product Segment Analysis
The instruments segment is predicted to dominate the microbiology testing market with a 38.7% revenue share over the analyzed period. The tightening quality regulations are creating a surge for high throughput and specificity during clinical evaluations, which are efficiently delivered by these components, specifically automated culture systems (ACSs). As evidence, the FDA mandated incorporation of ACSs in 90.4% of hospitals in the U.S. by the end of 2030 to prevent the risk of healthcare-associated infections (HAIs) epidemics, according to the guidelines published by the Centers for Disease Control and Prevention (CDC) in 2024. Besides, the segment's leadership can also be testified by a report from the World Trade Organization (WTO), underscoring a 9.5% increase in global exports of related equipment in 2023.
Application Segment Analysis
The clinical diagnostics segment is poised to hold a notable share of 28.8% in the microbiology testing market throughout the assessed timeline. The growing awareness about early detection and prevention is pushing worldwide healthcare authorities to cultivate adequate diagnostic measures, and hence they are actively investing in this sector. For instance, in 2024, the European Commission (EC) revealed that the AMR Action Plan of Europe set its aims to reduce diagnostic errors by 50.7% by 2030. In addition, the WHO underscored 40.6% of UTI cases around the globe being misdiagnosed without advanced PCR methods till 2023. These factors are collectively garnering a reliable demand and supply volume for molecular diagnostics.
Technology Segment Analysis
PCR technology is poised to command a considerable share of 22.9% in the microbiology testing market by the end of 2034. Ongoing advances and trends regarding the integration of next-generation technologies are amplifying the commercial value of this subtype, attracting more global MedTech pioneers to invest. Exemplifying the same, in 2023, Thermo Fisher allocated $2.6 billion to acquire Qiagen with an aim to solidify and expand its territory in this category. Besides, the sales volume of the company in rural areas of Europe increased by 25.5% after gaining FDA clearance for its portable PCR devices in 2024. Moreover, the integration of AI, which reduces reporting timeline by 30.7%, is also amplifying adoption of PCR in pathogen detection.
Our in-depth analysis of the microbiology testing market includes the following segments:
|
Segment |
Subsegments |
|
Product |
|
|
Application |
|
|
End user |
|
|
Technology |
|
